Compare FTAI Aviation Ltd (FTAI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Organon & Co. Common Stock — how do they compare? FTAI Aviation Ltd trades at $160.9 (market cap $16.75B), while Organon & Co. Common Stock trades at $13.75 (market cap $3.61B). The key difference: FTAI Aviation Ltd is far larger — about 4.6× Organon & Co. Common Stock's market cap, and FTAI Aviation Ltd pays the higher dividend (1.23%). Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 24 Days and Organon & Co. Common Stock for 0 Days on average.
| FTAI | OGN | |
|---|---|---|
Market Cap | $16.75B | $3.61B |
Volume | 2,940,634 | 1,808,049 |
Sector | Industrials | Health |
52-Week High | $310.04 | $13.81 |
52-Week Low | $152.80 | $5.70 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $19.87B | $11.03B |
Dividend Yield | 1.23% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $166.87, showing modest daily gains of 0.81% but facing bearish technical signals with 16 sell indicators versus 3 buy signals. The company reported strong revenue growth to $2.51 billion in 2025 with a 19.98% net profit margin, though recent quarters show earnings misses against expectations. Recent developments include a $500 million share repurchase program and acquisition of 27 Boeing 737-700 aircraft, signaling strategic expansion in aerospace services.
Despite technical weakness, FTAI maintains unanimous analyst buy ratings with a $321.25 consensus target representing 92% upside potential. Key risks include consecutive earnings misses and negative operating cash flow, while catalysts include the buyback program and aerospace sector growth. The stock presents a compelling value opportunity if operational execution improves to match analyst optimism.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
